ropivacain deltamedica 2 mg/ml injektionslösung
deltamedica gmbh (8129325) - ropivacainhydrochlorid-monohydrat - injektionslösung - ropivacainhydrochlorid-monohydrat (24086) 2,12 milligramm
ropivacain bioq 2 mg/ml infusionslösung
bioq pharma b.v. (8180295) - ropivacainhydrochlorid-monohydrat - infusionslösung - ropivacainhydrochlorid-monohydrat (24086) 2,12 milligramm
ropivacain piramal 10 mg/ml injektionslösung
piramal critical care italia s.p.a. (8147122) - ropivacainhydrochlorid-monohydrat - injektionslösung - ropivacainhydrochlorid-monohydrat (24086) 10,58 milligramm
ropivacain piramal 7,5 mg/ml injektionslösung
piramal critical care italia s.p.a. (8147122) - ropivacainhydrochlorid-monohydrat - injektionslösung - ropivacainhydrochlorid-monohydrat (24086) 7,94 milligramm
ropivacain piramal 5 mg/ml injektionslösung
piramal critical care italia s.p.a. (8147122) - ropivacainhydrochlorid-monohydrat - injektionslösung - ropivacainhydrochlorid-monohydrat (24086) 5,29 milligramm
ropivacain piramal 2 mg/ml injektionslösung
piramal critical care italia s.p.a. (8147122) - ropivacainhydrochlorid-monohydrat - injektionslösung - ropivacainhydrochlorid-monohydrat (24086) 2,12 milligramm
ropivacain piramal 2 mg/ml infusionslösung
piramal critical care italia s.p.a. (8147122) - ropivacainhydrochlorid-monohydrat - infusionslösung - ropivacainhydrochlorid-monohydrat (24086) 2,12 milligramm
zomig 2,5 mg schmelztabletten
eurimpharm arzneimittel gmbh - zolmitriptan - schmelztablette - zolmitriptan 2.5mg
clopidogrel sandoz 75 mg - filmtabletten
sandoz gmbh - clopidogrel hydrochlorid - clopidogrel
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antithrombotische mittel - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevation acute myocardial infarction, in kombination mit ass bei medizinisch behandelten patienten, für die eine thrombolytische therapie. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. weitere informationen finden sie in abschnitt 5.